Johnson & Johnson Reports registry Data for Gene therapy in Parkinson's disease

Johnson & Johnson today announced registry results for gene therapy in patients with Parkinson's disease. The study demonstrated that gene therapy demonstrates durable remissions compared to standard of care or placebo. These results provide important insights into the treatment of Parkinson's disease and support the continued development of gene therapy in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.